Editorial
Published on 19 Apr 2024
Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1411836
- 781 views
Type at least 3 characters
1,765 articles
Articles
Clinical Trial
Published on 19 Apr 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1386190
- 1,697 views
Review
Published on 18 Apr 2024
Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1389713
- 1,446 views
- 3 citations
Brief Research Report
Published on 18 Apr 2024
Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1344852
- 1,813 views
Case Report
Published on 08 Apr 2024
Sunitinib for adenocarcinoma of the rete testis: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1358133
- 863 views
Case Report
Published on 04 Apr 2024
Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1370666
- 1,092 views
- 2 citations
Review
Published on 28 Mar 2024
Therapeutic prospects of nectin-4 in cancer: applications and value
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1354543
- 7,244 views
- 4 citations
Original Research
Published on 25 Mar 2024
Pan-cancer and single-cell analyses identify CD44 as an immunotherapy response predictor and regulating macrophage polarization and tumor progression in colorectal cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1380821
- 2,921 views
- 2 citations
Retraction
Published on 20 Mar 2024
Retraction: Establishment of criteria for molecular differential diagnosis of MPC and IPM
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1399853
- 682 views
Original Research
Published on 14 Mar 2024
DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1356778
- 1,774 views
- 1 citation
Case Report
Published on 14 Mar 2024
Case report: Targeted treatment strategies for Erdheim-Chester disease
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1305518
- 1,833 views
Case Report
Published on 11 Mar 2024
Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1363069
- 1,611 views
Review
Published on 08 Mar 2024
Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1376916
- 1,672 views
- 3 citations
Mini Review
Published on 07 Mar 2024
Experimental evidence for anti-metastatic actions of apigenin: a mini review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1380194
- 1,294 views
Original Research
Published on 07 Mar 2024
Sulforaphane inhibits the growth of prostate cancer by regulating the microRNA-3919/DJ-1 axis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1361152
- 1,574 views
- 1 citation
Review
Published on 06 Mar 2024
Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1371421
- 5,459 views
- 1 citation